Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives. He is the world’s leading advocate for human enhancement and believes in advancing scientific progress to usher in an era of physical and mental potential, improving life for all.

Apeiron Investment Group, Christian’s family office and private investment firm, has more than USD 2.5 billion under management and 50 people in London, New York City, Abu Dhabi and Berlin. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech, Natural Resources & Clean Energy, and Experiences, Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns.

Christian’s current areas of focus include:

Christian is recognized for leading the current psychedelics renaissance which he believes will end the global mental health crisis. atai Life Sciences (Nasdaq: ATAI), founded by Christian, is developing psychedelic compounds including psilocybin, ketamine, DMT, and ibogaine, and their potential use as approved medical treatments.

He has founded two biotech companies, Rejuveron Life Sciences and Cambrian Biopharma, that are developing medical drugs with the aim to significantly prolong the human life and health span. He is also a sponsor of the XPRIZE Healthspan, the $101 million competition that will incentivize new therapeutics to improve healthy aging and close the gap between life and health expectancy.

Christian is also a driving force behind the world’s leading BCI developer, Blackrock Neurotech. The Utah-based company is developing innovative brain technologies provide new hope for people with paralysis and other neurological disorders – and already has almost 50 BCIs implanted in patients’ brains.